HC Wainwright & Co. Maintains Buy on Immunogen, Raises Price Target to $21
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $15 to $21.
June 13, 2023 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $15 to $21.
The news of HC Wainwright & Co. maintaining a Buy rating on Immunogen and raising the price target from $15 to $21 is positive for the stock. This indicates that the analyst has a bullish outlook on the company, which could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100